Manufacturing
Vein-to-Vein Time
v2v time
TL;DR
Elapsed time from apheresis collection to infusion of the engineered cell therapy back into the patient — a critical performance metric for autologous therapies.
Vein-to-Vein (V2V) time spans patient apheresis → cryo/ship → manufacturing → QC release → ship → infusion. It is both a patient-outcome lever and a logistics KPI. Each leg generates GMP records, chain-of-identity checks, and chain-of-custody scans.
V5 tracks V2V as a live KPI across the patient cohort with each step's actuals vs target visible to the manufacturing and clinical team.
Regulatory anchors
- 21 CFR 1271
- FDA CGT Guidance
Industries that live with this
Related terms
Software that covers Vein-to-Vein Time
V5 Ultimate CGT Manufacturing Software
Autologous COI from apheresis to infusion, allogeneic lot genealogy from donor to bag, viral-vector eBR, ISBT 128 / SEC-178…
V5 Ultimate Tissue Bank Software
Donor eligibility as a hard gate, DRAI on the kiosk, ISBT 128 labelling, lookback as a single query, cGTP processing records, and…
V5 Ultimate (FDA Compliance)
V5 Ultimate is a single-platform FDA compliance system for US manufacturers regulated under 21 CFR — pharma (210/211), medical…
Want to see Vein-to-Vein Time in V5?
Free trial, no credit card, onboard in days, not months.